Status:

TERMINATED

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Lead Sponsor:

Puma Biotechnology, Inc.

Conditions:

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Metastatic Cervical Cancer

Eligibility:

All Genders

18+ years

Brief Summary

This is a multi-center, observational genomic screening protocol to identify participants whose tumors harbor somatic mutations in the ERBB2 (HER2) gene, as measured in circulating tumor DNA (ctDNA) ....

Eligibility Criteria

Inclusion

  • Women and men who are ≥18 years old at signing of informed consent
  • Eastern Cooperative Oncology Group (ECOG) status of 0 to 2
  • Provide written informed consent to participate in the study and for circulating tumor DNA screening
  • Must be able to provide blood sample(s) for HER2 mutation testing
  • Participants with imaging or histologically confirmed, HR-positive, HER2-negative MBC who are presently receiving or have received CDK4/6 inhibitor as a prior therapy in any setting, or participants with imaging or histologically confirmed metastatic cervical cancer
  • At least one measurable lesion, as defined by RECIST v1.1

Exclusion

  • Participants with breast cancer with known HER2-positive or HER2-amplified tumors
  • Participants with breast cancer with HR-negative tumors
  • Participants who have received HER2-directed TKI
  • Participants with previously documented somatic KRAS activating mutation

Key Trial Info

Start Date :

March 14 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 21 2021

Estimated Enrollment :

1583 Patients enrolled

Trial Details

Trial ID

NCT03786107

Start Date

March 14 2019

End Date

January 21 2021

Last Update

May 19 2021

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

Magee-Womens Hospital of UPMC

Pittsburgh, Pennsylvania, United States, 15213

2

Institut Curie

Saint-Cloud, France, 92210

3

Cork University Hospital

Wilton, Cork, Ireland, T12 DC4A

4

St. Vincent's University Hospital

Elm Park, Dublin, Ireland, D04 T6F4

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib | DecenTrialz